Vical Incorporated to Present at 3rd Annual Cancer Immunotherapy Conference
Published: Sep 27, 2012
SAN DIEGO, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will present at the MD Becker Partners' 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 4, at 1:15 p.m. ET, at the New York Academy of Medicine. Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of its Allovectin® immunotherapy program, including mechanisms of action, summary clinical results, and current status and outlook in the ongoing Phase 3 registration trial in patients with metastatic melanoma.